Dr Mark Mcelhannon, MD | |
1000 Corporate Center Dr, Suite 200, Morrow, GA 30260-4180 | |
(770) 968-6464 | |
(770) 968-6455 |
Full Name | Dr Mark Mcelhannon |
---|---|
Gender | Male |
Speciality | Hospitalist |
Experience | 31 Years |
Location | 1000 Corporate Center Dr, Morrow, Georgia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083675086 | NPI | - | NPPES |
000825371C | Medicaid | GA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | M2709 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Christus Santa Rosa Hospital-san Marcos | San marcos, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Hospitalist Medicine Physicians Of Texas Pllc | 3476688318 | 951 |
South Texas Physician Services, Pllc | 5890145783 | 11 |
News Archive
Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.
An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago.
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
According to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, patients suffering from chronic primary insomnia (PIs) have higher levels of brain activation compared to normal sleepers during a working memory test.
The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has also disclosed a tool to predict the biological activity of any molecule, even when no experimental data are available.
› Verified 8 days ago
Entity Name | Cogent Healthcare Of Texas Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1992722953 PECOS PAC ID: 8628076924 Enrollment ID: O20061121000364 |
News Archive
Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.
An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago.
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
According to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, patients suffering from chronic primary insomnia (PIs) have higher levels of brain activation compared to normal sleepers during a working memory test.
The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has also disclosed a tool to predict the biological activity of any molecule, even when no experimental data are available.
› Verified 8 days ago
Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20100317001021 |
News Archive
Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.
An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago.
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
According to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, patients suffering from chronic primary insomnia (PIs) have higher levels of brain activation compared to normal sleepers during a working memory test.
The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has also disclosed a tool to predict the biological activity of any molecule, even when no experimental data are available.
› Verified 8 days ago
Entity Name | Hospitalist Medicine Physicians Of Texas San Marcos Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1598244774 PECOS PAC ID: 2961754817 Enrollment ID: O20181004001119 |
News Archive
Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.
An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago.
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
According to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, patients suffering from chronic primary insomnia (PIs) have higher levels of brain activation compared to normal sleepers during a working memory test.
The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has also disclosed a tool to predict the biological activity of any molecule, even when no experimental data are available.
› Verified 8 days ago
Entity Name | South Texas Physician Services, Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1598546772 PECOS PAC ID: 5890145783 Enrollment ID: O20231218003973 |
News Archive
Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.
An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago.
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
According to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, patients suffering from chronic primary insomnia (PIs) have higher levels of brain activation compared to normal sleepers during a working memory test.
The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has also disclosed a tool to predict the biological activity of any molecule, even when no experimental data are available.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Mark Mcelhannon, MD 303 Parkway Dr Ne, Suite 418, Atlanta, GA 30312-1212 Ph: (404) 265-6371 | Dr Mark Mcelhannon, MD 1000 Corporate Center Dr, Suite 200, Morrow, GA 30260-4180 Ph: (770) 968-6464 |
News Archive
Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.
An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago.
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
According to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, patients suffering from chronic primary insomnia (PIs) have higher levels of brain activation compared to normal sleepers during a working memory test.
The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has also disclosed a tool to predict the biological activity of any molecule, even when no experimental data are available.
› Verified 8 days ago
Rana Botlani Esfahani, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1000 Corporate Center Dr, Ste 200, Morrow, GA 30260 Phone: 770-968-6464 | |
Alvin H Webster, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 6522 Peacock Blvd, Morrow, GA 30260 Phone: 678-778-4591 Fax: 770-961-0056 | |
Dr. Evelyn Campbell-bayaan, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1331 Mount Zion Rd, Morrow, GA 30260 Phone: 770-629-3217 | |
Rhonda R. Freeman, NP Family Medicine Medicare: Medicare Enrolled Practice Location: 2005 Mount Zion Rd, Morrow, GA 30260 Phone: 770-919-5250 | |
Dr. George W Brown Iv, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Corporate Center Dr, Ste 200, Morrow, GA 30260 Phone: 770-968-6464 Fax: 770-968-6455 | |
Gabriella Eliese Maris, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Corporate Center Dr, Suite 200, Morrow, GA 30260 Phone: 770-968-6464 Fax: 770-968-6455 |